Arch Biopartners Inc.
Arch Biopartners Inc. (ACHFF) Financial Performance & Income Statement Overview
Explore the financials of Arch Biopartners Inc. (ACHFF), including yearly and quarterly data on income, cash flow, and balance sheets.
Arch Biopartners Inc. (ACHFF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Arch Biopartners Inc. ACHFF financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $473104.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | -$473104.00 | $0.00 |
| Gross Profit Ratio | $0.00 | $0.00 | ||
| R&D Expenses | $78185.00 | $365571.00 | $440274.00 | $2.70M |
| SG&A Expenses | $255593.00 | $305247.00 | $280921.00 | $535678.00 |
| Operating Expenses | $357317.00 | $670818.00 | $389829.00 | $3.24M |
| Total Costs & Expenses | $357317.00 | -$670818.00 | $862933.00 | $3.24M |
| Interest Income | $0.00 | $0.00 | $0.00 | $4072.00 |
| Interest Expense | $70151.00 | $116730.00 | $95281.00 | $88682.00 |
| Depreciation & Amortization | $0.00 | $0.00 | $754025.00 | $0.00 |
| EBITDA | -$346150.00 | -$987228.00 | -$35257.00 | -$1.06M |
| EBITDA Ratio | ||||
| Operating Income | -$357317.00 | -$670818.00 | -$862933.00 | -$3.24M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | -$58984.00 | -$433138.00 | -$21632.00 | -$4481.00 |
| Income Before Tax | -$416301.00 | -$1.10M | -$884565.00 | -$1.15M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$416301.00 | -$1.10M | -$884565.00 | -$1.15M |
| Net Income Ratio | ||||
| EPS | -$0.006 | -$0.02 | -$0.01 | -$0.02 |
| Diluted EPS | -$0.006 | -$0.02 | -$0.01 | -$0.02 |
| Weighted Avg Shares Outstanding | $64.94M | $64.65M | $62.76M | $62.76M |
| Weighted Avg Shares Outstanding (Diluted) | $64.94M | $64.65M | $62.76M | $62.76M |
Financial performance has remained strong, with revenue growing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$357317.00 in Q1 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$346150.00. Net income rose to -$416301.00, keeping EPS at -$0.006. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan